Listed

UNITED THERAPEUTICS Corp

UTHRNasdaqCIK 1082554HealthcareFiscal year ends Dec 31

Latest reported revenue, Q2 FY2026$783.3mRevenue, Q2 FY2026, three months to 2026-06-30$783.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-05, accession 0001082554-26-000027.Report this figureThree months to Jun 30, 2026, from the 10-Q filed Aug 5, 2026.

Latest quarter: Q2 FY2026

Three months to Jun 30, 2026, against the same quarter a year earlier.

  • Revenue$783.3mRevenue, Q2 FY2026, three months to 2026-06-30$783.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-05, accession 0001082554-26-000027.Report this figure−1.9% on a year earlier
  • Gross margin87.3%Gross margin, Q2 FY2026, three months to 2026-06-30. gross profit / revenueGross profit: $683.8m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-08-05, accession 0001082554-26-000027.Revenue: $783.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-05, accession 0001082554-26-000027.Report this figure−1.7 pts on a year earlier
  • Operating margin42.2%Operating margin, Q2 FY2026, three months to 2026-06-30. operating income / revenueOperating income: $330.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-05, accession 0001082554-26-000027.Revenue: $783.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-05, accession 0001082554-26-000027.Report this figure−3.4 pts on a year earlier
  • Net margin42.5%Net margin, Q2 FY2026, three months to 2026-06-30. net income / revenueNet income: $333.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-05, accession 0001082554-26-000027.Revenue: $783.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-05, accession 0001082554-26-000027.Report this figure+3.8 pts on a year earlier
  • Diluted EPS$7.27Diluted EPS, Q2 FY2026, three months to 2026-06-30$7.27 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-05, accession 0001082554-26-000027.Report this figure+13.4% on a year earlier
  • Free cash flow$205.6mFree cash flow, Q2 FY2026, three months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: $313.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-05, accession 0001082554-26-000027. Derived: 6-month figure less the 3-month figure.Capital expenditure: $108.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-05, accession 0001082554-26-000027. Derived: 6-month figure less the 3-month figure.Report this figure+58.8% on a year earlier

Last eight quarters

Full statements
Revenue$783.3mGross margin 87.3%
Diluted EPS$7.27, Q2 FY2026
Free cash flow$205.6m, Q2 FY2026
UNITED THERAPEUTICS Corp, key figures for the last eight quarters
Line itemUnitQ3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30Shape over the periods
Revenue$m749Revenue, Q3 FY2024, three months to 2024-09-30$748.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-10-29, accession 0001082554-25-000034.Report this figure736Revenue, Q4 FY2024, three months to 2024-12-31$735.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-25, accession 0001082554-26-000006. Derived: 12-month figure less the 9-month figure.Report this figure794Revenue, Q1 FY2025, three months to 2025-03-31$794.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-06, accession 0001082554-26-000020.Report this figure799Revenue, Q2 FY2025, three months to 2025-06-30$798.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-05, accession 0001082554-26-000027.Report this figure800Revenue, Q3 FY2025, three months to 2025-09-30$799.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-10-29, accession 0001082554-25-000034.Report this figure790Revenue, Q4 FY2025, three months to 2025-12-31$790.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-25, accession 0001082554-26-000006. Derived: 12-month figure less the 9-month figure.Report this figure782Revenue, Q1 FY2026, three months to 2026-03-31$781.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-06, accession 0001082554-26-000020.Report this figure783Revenue, Q2 FY2026, three months to 2026-06-30$783.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-05, accession 0001082554-26-000027.Report this figure
Gross margin%88.9%Gross margin, Q3 FY2024, three months to 2024-09-30. gross profit / revenueGross profit: $665.8m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2025-10-29, accession 0001082554-25-000034.Revenue: $748.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-10-29, accession 0001082554-25-000034.Report this figure89.7%Gross margin, Q4 FY2024, three months to 2024-12-31. gross profit / revenueGross profit: $660.0m. XBRL concept us-gaap:GrossProfit. 10-K filed 2026-02-25, accession 0001082554-26-000006. Derived: 12-month figure less the 9-month figure.Revenue: $735.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-25, accession 0001082554-26-000006. Derived: 12-month figure less the 9-month figure.Report this figure88.4%Gross margin, Q1 FY2025, three months to 2025-03-31. gross profit / revenueGross profit: $701.9m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-05-06, accession 0001082554-26-000020.Revenue: $794.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-06, accession 0001082554-26-000020.Report this figure89.0%Gross margin, Q2 FY2025, three months to 2025-06-30. gross profit / revenueGross profit: $711.0m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-08-05, accession 0001082554-26-000027.Revenue: $798.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-05, accession 0001082554-26-000027.Report this figure87.4%Gross margin, Q3 FY2025, three months to 2025-09-30. gross profit / revenueGross profit: $698.6m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2025-10-29, accession 0001082554-25-000034.Revenue: $799.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-10-29, accession 0001082554-25-000034.Report this figure86.9%Gross margin, Q4 FY2025, three months to 2025-12-31. gross profit / revenueGross profit: $686.8m. XBRL concept us-gaap:GrossProfit. 10-K filed 2026-02-25, accession 0001082554-26-000006. Derived: 12-month figure less the 9-month figure.Revenue: $790.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-25, accession 0001082554-26-000006. Derived: 12-month figure less the 9-month figure.Report this figure82.9%Gross margin, Q1 FY2026, three months to 2026-03-31. gross profit / revenueGross profit: $648.1m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-05-06, accession 0001082554-26-000020.Revenue: $781.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-06, accession 0001082554-26-000020.Report this figure87.3%Gross margin, Q2 FY2026, three months to 2026-06-30. gross profit / revenueGross profit: $683.8m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-08-05, accession 0001082554-26-000027.Revenue: $783.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-05, accession 0001082554-26-000027.Report this figure
Operating margin%45.8%Operating margin, Q3 FY2024, three months to 2024-09-30. operating income / revenueOperating income: $343.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-10-29, accession 0001082554-25-000034.Revenue: $748.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-10-29, accession 0001082554-25-000034.Report this figure48.6%Operating margin, Q4 FY2024, three months to 2024-12-31. operating income / revenueOperating income: $357.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-25, accession 0001082554-26-000006. Derived: 12-month figure less the 9-month figure.Revenue: $735.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-25, accession 0001082554-26-000006. Derived: 12-month figure less the 9-month figure.Report this figure48.2%Operating margin, Q1 FY2025, three months to 2025-03-31. operating income / revenueOperating income: $382.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-06, accession 0001082554-26-000020.Revenue: $794.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-06, accession 0001082554-26-000020.Report this figure45.6%Operating margin, Q2 FY2025, three months to 2025-06-30. operating income / revenueOperating income: $364.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-05, accession 0001082554-26-000027.Revenue: $798.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-05, accession 0001082554-26-000027.Report this figure48.6%Operating margin, Q3 FY2025, three months to 2025-09-30. operating income / revenueOperating income: $388.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-10-29, accession 0001082554-25-000034.Revenue: $799.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-10-29, accession 0001082554-25-000034.Report this figure45.1%Operating margin, Q4 FY2025, three months to 2025-12-31. operating income / revenueOperating income: $356.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-25, accession 0001082554-26-000006. Derived: 12-month figure less the 9-month figure.Revenue: $790.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-25, accession 0001082554-26-000006. Derived: 12-month figure less the 9-month figure.Report this figure41.7%Operating margin, Q1 FY2026, three months to 2026-03-31. operating income / revenueOperating income: $325.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-06, accession 0001082554-26-000020.Revenue: $781.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-06, accession 0001082554-26-000020.Report this figure42.2%Operating margin, Q2 FY2026, three months to 2026-06-30. operating income / revenueOperating income: $330.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-05, accession 0001082554-26-000027.Revenue: $783.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-05, accession 0001082554-26-000027.Report this figure
Net margin%41.3%Net margin, Q3 FY2024, three months to 2024-09-30. net income / revenueNet income: $309.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-10-29, accession 0001082554-25-000034.Revenue: $748.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-10-29, accession 0001082554-25-000034.Report this figure40.9%Net margin, Q4 FY2024, three months to 2024-12-31. net income / revenueNet income: $301.3m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-25, accession 0001082554-26-000006. Derived: 12-month figure less the 9-month figure.Revenue: $735.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-25, accession 0001082554-26-000006. Derived: 12-month figure less the 9-month figure.Report this figure40.6%Net margin, Q1 FY2025, three months to 2025-03-31. net income / revenueNet income: $322.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-06, accession 0001082554-26-000020.Revenue: $794.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-06, accession 0001082554-26-000020.Report this figure38.8%Net margin, Q2 FY2025, three months to 2025-06-30. net income / revenueNet income: $309.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-05, accession 0001082554-26-000027.Revenue: $798.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-05, accession 0001082554-26-000027.Report this figure42.4%Net margin, Q3 FY2025, three months to 2025-09-30. net income / revenueNet income: $338.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-10-29, accession 0001082554-25-000034.Revenue: $799.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-10-29, accession 0001082554-25-000034.Report this figure46.1%Net margin, Q4 FY2025, three months to 2025-12-31. net income / revenueNet income: $364.3m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-25, accession 0001082554-26-000006. Derived: 12-month figure less the 9-month figure.Revenue: $790.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-25, accession 0001082554-26-000006. Derived: 12-month figure less the 9-month figure.Report this figure35.2%Net margin, Q1 FY2026, three months to 2026-03-31. net income / revenueNet income: $274.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-06, accession 0001082554-26-000020.Revenue: $781.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-06, accession 0001082554-26-000020.Report this figure42.5%Net margin, Q2 FY2026, three months to 2026-06-30. net income / revenueNet income: $333.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-05, accession 0001082554-26-000027.Revenue: $783.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-05, accession 0001082554-26-000027.Report this figure
Diluted EPS$ per share6.39Diluted EPS, Q3 FY2024, three months to 2024-09-30$6.39 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-10-29, accession 0001082554-25-000034.Report this figurenot reported (Diluted EPS not reported)6.63Diluted EPS, Q1 FY2025, three months to 2025-03-31$6.63 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-06, accession 0001082554-26-000020.Report this figure6.41Diluted EPS, Q2 FY2025, three months to 2025-06-30$6.41 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-05, accession 0001082554-26-000027.Report this figure7.16Diluted EPS, Q3 FY2025, three months to 2025-09-30$7.16 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-10-29, accession 0001082554-25-000034.Report this figurenot reported (Diluted EPS not reported)5.82Diluted EPS, Q1 FY2026, three months to 2026-03-31$5.82 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-06, accession 0001082554-26-000020.Report this figure7.27Diluted EPS, Q2 FY2026, three months to 2026-06-30$7.27 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-05, accession 0001082554-26-000027.Report this figure
Free cash flow$m301Free cash flow, Q3 FY2024, three months to 2024-09-30. operating cash flow − capital expenditureOperating cash flow: $377.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-10-29, accession 0001082554-25-000034. Derived: 9-month figure less the 6-month figure.Capital expenditure: $76.5m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-10-29, accession 0001082554-25-000034. Derived: 9-month figure less the 6-month figure.Report this figure255Free cash flow, Q4 FY2024, three months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: $341.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-25, accession 0001082554-26-000006. Derived: 12-month figure less the 9-month figure.Capital expenditure: $86.7m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-25, accession 0001082554-26-000006. Derived: 12-month figure less the 9-month figure.Report this figure386Free cash flow, Q1 FY2025, three months to 2025-03-31. operating cash flow − capital expenditureOperating cash flow: $461.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-06, accession 0001082554-26-000020.Capital expenditure: $74.9m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-06, accession 0001082554-26-000020.Report this figure130Free cash flow, Q2 FY2025, three months to 2025-06-30. operating cash flow − capital expenditureOperating cash flow: $191.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-05, accession 0001082554-26-000027. Derived: 6-month figure less the 3-month figure.Capital expenditure: $62.2m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-05, accession 0001082554-26-000027. Derived: 6-month figure less the 3-month figure.Report this figure352Free cash flow, Q3 FY2025, three months to 2025-09-30. operating cash flow − capital expenditureOperating cash flow: $562.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-10-29, accession 0001082554-25-000034. Derived: 9-month figure less the 6-month figure.Capital expenditure: $210.5m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-10-29, accession 0001082554-25-000034. Derived: 9-month figure less the 6-month figure.Report this figure173Free cash flow, Q4 FY2025, three months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: $346.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-25, accession 0001082554-26-000006. Derived: 12-month figure less the 9-month figure.Capital expenditure: $172.9m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-25, accession 0001082554-26-000006. Derived: 12-month figure less the 9-month figure.Report this figure363Free cash flow, Q1 FY2026, three months to 2026-03-31. operating cash flow − capital expenditureOperating cash flow: $463.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-06, accession 0001082554-26-000020.Capital expenditure: $100.8m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-06, accession 0001082554-26-000020.Report this figure206Free cash flow, Q2 FY2026, three months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: $313.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-05, accession 0001082554-26-000027. Derived: 6-month figure less the 3-month figure.Capital expenditure: $108.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-05, accession 0001082554-26-000027. Derived: 6-month figure less the 3-month figure.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Last five fiscal years

Revenue$3.18bnGross margin 87.9%
Diluted EPS$27.86, FY2025
Free cash flow$1.04bn, FY2025
UNITED THERAPEUTICS Corp, key figures for the last five fiscal years
Line itemUnitFY20212021-12-31FY20222022-12-31FY20232023-12-31FY20242024-12-31FY20252025-12-31Shape over the periods
Revenue$m1,686Revenue, FY2021, twelve months to 2021-12-31$1.69bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-02-21, accession 0001082554-24-000005.Report this figure1,936Revenue, FY2022, twelve months to 2022-12-31$1.94bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-02-26, accession 0001082554-25-000005.Report this figure2,328Revenue, FY2023, twelve months to 2023-12-31$2.33bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-25, accession 0001082554-26-000006.Report this figure2,877Revenue, FY2024, twelve months to 2024-12-31$2.88bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-25, accession 0001082554-26-000006.Report this figure3,183Revenue, FY2025, twelve months to 2025-12-31$3.18bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-25, accession 0001082554-26-000006.Report this figure
Gross margin%92.7%Gross margin, FY2021, twelve months to 2021-12-31. gross profit / revenueGross profit: $1.56bn. XBRL concept us-gaap:GrossProfit. 10-K filed 2024-02-21, accession 0001082554-24-000005.Revenue: $1.69bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-02-21, accession 0001082554-24-000005.Report this figure92.2%Gross margin, FY2022, twelve months to 2022-12-31. gross profit / revenueGross profit: $1.78bn. XBRL concept us-gaap:GrossProfit. 10-K filed 2025-02-26, accession 0001082554-25-000005.Revenue: $1.94bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-02-26, accession 0001082554-25-000005.Report this figure88.9%Gross margin, FY2023, twelve months to 2023-12-31. gross profit / revenueGross profit: $2.07bn. XBRL concept us-gaap:GrossProfit. 10-K filed 2026-02-25, accession 0001082554-26-000006.Revenue: $2.33bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-25, accession 0001082554-26-000006.Report this figure89.2%Gross margin, FY2024, twelve months to 2024-12-31. gross profit / revenueGross profit: $2.57bn. XBRL concept us-gaap:GrossProfit. 10-K filed 2026-02-25, accession 0001082554-26-000006.Revenue: $2.88bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-25, accession 0001082554-26-000006.Report this figure87.9%Gross margin, FY2025, twelve months to 2025-12-31. gross profit / revenueGross profit: $2.80bn. XBRL concept us-gaap:GrossProfit. 10-K filed 2026-02-25, accession 0001082554-26-000006.Revenue: $3.18bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-25, accession 0001082554-26-000006.Report this figure
Operating margin%33.0%Operating margin, FY2021, twelve months to 2021-12-31. operating income / revenueOperating income: $555.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2024-02-21, accession 0001082554-24-000005.Revenue: $1.69bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-02-21, accession 0001082554-24-000005.Report this figure50.6%Operating margin, FY2022, twelve months to 2022-12-31. operating income / revenueOperating income: $979.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-02-26, accession 0001082554-25-000005.Revenue: $1.94bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-02-26, accession 0001082554-25-000005.Report this figure50.9%Operating margin, FY2023, twelve months to 2023-12-31. operating income / revenueOperating income: $1.18bn. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-25, accession 0001082554-26-000006.Revenue: $2.33bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-25, accession 0001082554-26-000006.Report this figure47.9%Operating margin, FY2024, twelve months to 2024-12-31. operating income / revenueOperating income: $1.38bn. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-25, accession 0001082554-26-000006.Revenue: $2.88bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-25, accession 0001082554-26-000006.Report this figure46.9%Operating margin, FY2025, twelve months to 2025-12-31. operating income / revenueOperating income: $1.49bn. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-25, accession 0001082554-26-000006.Revenue: $3.18bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-25, accession 0001082554-26-000006.Report this figure
Net margin%28.2%Net margin, FY2021, twelve months to 2021-12-31. net income / revenueNet income: $475.8m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2024-02-21, accession 0001082554-24-000005.Revenue: $1.69bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-02-21, accession 0001082554-24-000005.Report this figure37.6%Net margin, FY2022, twelve months to 2022-12-31. net income / revenueNet income: $727.3m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-02-26, accession 0001082554-25-000005.Revenue: $1.94bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-02-26, accession 0001082554-25-000005.Report this figure42.3%Net margin, FY2023, twelve months to 2023-12-31. net income / revenueNet income: $984.8m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-25, accession 0001082554-26-000006.Revenue: $2.33bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-25, accession 0001082554-26-000006.Report this figure41.5%Net margin, FY2024, twelve months to 2024-12-31. net income / revenueNet income: $1.20bn. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-25, accession 0001082554-26-000006.Revenue: $2.88bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-25, accession 0001082554-26-000006.Report this figure41.9%Net margin, FY2025, twelve months to 2025-12-31. net income / revenueNet income: $1.33bn. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-25, accession 0001082554-26-000006.Revenue: $3.18bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-25, accession 0001082554-26-000006.Report this figure
Diluted EPS$ per share10.06Diluted EPS, FY2021, twelve months to 2021-12-31$10.06 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2024-02-21, accession 0001082554-24-000005.Report this figure15.00Diluted EPS, FY2022, twelve months to 2022-12-31$15.00 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2025-02-26, accession 0001082554-25-000005.Report this figure19.81Diluted EPS, FY2023, twelve months to 2023-12-31$19.81 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-25, accession 0001082554-26-000006.Report this figure24.64Diluted EPS, FY2024, twelve months to 2024-12-31$24.64 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-25, accession 0001082554-26-000006.Report this figure27.86Diluted EPS, FY2025, twelve months to 2025-12-31$27.86 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-25, accession 0001082554-26-000006.Report this figure
Free cash flow$m477Free cash flow, FY2021, twelve months to 2021-12-31. operating cash flow − capital expenditureOperating cash flow: $598.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2024-02-21, accession 0001082554-24-000005.Capital expenditure: $120.8m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2024-02-21, accession 0001082554-24-000005.Report this figure664Free cash flow, FY2022, twelve months to 2022-12-31. operating cash flow − capital expenditureOperating cash flow: $802.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-02-26, accession 0001082554-25-000005.Capital expenditure: $138.8m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-02-26, accession 0001082554-25-000005.Report this figure748Free cash flow, FY2023, twelve months to 2023-12-31. operating cash flow − capital expenditureOperating cash flow: $978.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-25, accession 0001082554-26-000006.Capital expenditure: $230.4m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-25, accession 0001082554-26-000006.Report this figure1,081Free cash flow, FY2024, twelve months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: $1.33bn. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-25, accession 0001082554-26-000006.Capital expenditure: $246.5m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-25, accession 0001082554-26-000006.Report this figure1,041Free cash flow, FY2025, twelve months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: $1.56bn. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-25, accession 0001082554-26-000006.Capital expenditure: $520.5m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-25, accession 0001082554-26-000006.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Insider purchases and sales

All insider transactions

The last 20 open-market transactions reported on Form 4 (codes P and S). The reported price is the price per share the insider stated on the form: filing data, not a market price.

By month, by reported value, last 24 monthsPurchases $0Sales $27.6m
UNITED THERAPEUTICS Corp, open-market insider transactions
DateInsiderTransactionSharesReported priceValueFiling
2026-10-28Rothblatt Martine aChairperson & CEO, Director, Officer Sale80$588.3913$47.1kForm 4
2026-10-28Rothblatt Martine aChairperson & CEO, Director, Officer Sale986$587.2653$579.0kForm 4
2026-10-28Rothblatt Martine aChairperson & CEO, Director, Officer Sale3,086$586.3694$1.8mForm 4
2026-10-28Rothblatt Martine aChairperson & CEO, Director, Officer Sale1,902$585.3585$1.1mForm 4
2026-10-28Rothblatt Martine aChairperson & CEO, Director, Officer Sale2,625$584.4314$1.5mForm 4
2026-10-28Rothblatt Martine aChairperson & CEO, Director, Officer Sale821$583.5017$479.1kForm 4
2026-10-27Rothblatt Martine aChairperson & CEO, Director, Officer Sale80$592.835$47.4kForm 4
2026-10-27Rothblatt Martine aChairperson & CEO, Director, Officer Sale600$592.054$355.2kForm 4
2026-10-27Rothblatt Martine aChairperson & CEO, Director, Officer Sale700$590.9877$413.7kForm 4
2026-10-27Rothblatt Martine aChairperson & CEO, Director, Officer Sale1,003$589.9833$591.8kForm 4
2026-10-27Rothblatt Martine aChairperson & CEO, Director, Officer Sale1,597$588.9463$940.5kForm 4
2026-10-27Rothblatt Martine aChairperson & CEO, Director, Officer Sale1,320$587.8821$776.0kForm 4
2026-10-27Rothblatt Martine aChairperson & CEO, Director, Officer Sale1,417$586.9254$831.7kForm 4
2026-10-27Rothblatt Martine aChairperson & CEO, Director, Officer Sale470$585.7166$275.3kForm 4
2026-10-27Rothblatt Martine aChairperson & CEO, Director, Officer Sale1,417$584.8289$828.7kForm 4
2026-10-27Rothblatt Martine aChairperson & CEO, Director, Officer Sale807$583.9443$471.2kForm 4
2026-10-27Rothblatt Martine aChairperson & CEO, Director, Officer Sale89$582.6649$51.9kForm 4
2026-10-26Rothblatt Martine aChairperson & CEO, Director, Officer Sale806$592.9168$477.9kForm 4
2026-10-26Rothblatt Martine aChairperson & CEO, Director, Officer Sale694$591.60$410.6kForm 4
2026-10-26Rothblatt Martine aChairperson & CEO, Director, Officer Sale680$590.5669$401.6kForm 4

Funds that report holding it

All funds

From each manager's latest Form 13F, largest reported value first. Reported value is as filed at the quarter end: filing data, not a price. A put or call is an option position, not shares held.

Funds that report holding UNITED THERAPEUTICS Corp
FundQuarter endedReported valueSharesPut or callChange on the quarter before
BlackRock, Inc.2026-06-30$2.87bn5,294,529Reduced−105,120
Avoro Capital Advisors LLC2026-06-30$1.51bn2,777,777Added+147,777
VANGUARD PORTFOLIO MANAGEMENT LLC2026-06-30$1.04bn1,919,429Reduced−84,313
VANGUARD CAPITAL MANAGEMENT LLC2026-06-30$1.04bn1,918,256Reduced−39,283
STATE STREET CORP2026-06-30$1.03bn1,898,064Added+54,101
RENAISSANCE TECHNOLOGIES LLC2026-06-30$925.8m1,708,739Reduced−78,280
WELLINGTON MANAGEMENT GROUP LLP2026-06-30$747.2m1,379,025Reduced−885,222
GEODE CAPITAL MANAGEMENT, LLC2026-06-30$538.9m996,598Reduced−236,431
JANUS HENDERSON GROUP PLC2026-03-31$514.0m866,930Not compared
Jupiter Topco LLC2026-06-30$450.1m831,129Not compared

Recent filings

All 3,345 filings

Reports and events: 10-K, 10-Q, 8-K, proxy statements and ownership schedules.

UNITED THERAPEUTICS Corp, recent filings
FiledFormWhat it isAccession number
2026-10-2207:00 ET8-K8.01 Other events; 9.01 Financial statements and exhibits0001104659-26-117964
2026-10-1407:00 ET8-K8.01 Other events; 9.01 Financial statements and exhibits0001104659-26-115723
2026-09-0817:12 ET8-K1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001104659-26-105953
2026-08-0506:33 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001082554-26-000028
2026-08-0506:31 ET10-QQuarterly reportPeriod 2026-06-300001082554-26-000027
2026-07-2307:00 ET8-K5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001104659-26-086068
2026-06-2916:32 ET8-K5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits0001104659-26-078865
2026-05-0606:31 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001082554-26-000021
2026-05-0606:30 ET10-QQuarterly reportPeriod 2026-03-310001082554-26-000020
2026-04-2906:33 ETDEF 14AProxy statementPeriod 2026-06-260001082554-26-000009

Latest annual report

Form 10-K for the fiscal year ended Dec 31, 2025Filed Feb 25, 2026. Its page lists the documents and the extracted sections, such as Business and Risk factors.

Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by [object Promise].Forecast this quarter

About the filer

CIK
1082554
Tickers
UTHR
Exchange
Nasdaq
SIC code
2834 Pharmaceutical Preparations
Sector
Healthcare
Fiscal year ends
Dec 31
Incorporated in
DE
Filer category
Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 29, 2026, 16:32 ET. Listed shows no prices and gives no investment advice.